EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM TWO RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDIES

被引：7
|
作者：
Morand, E. F. [1 ]
Tanaka, Y. [2 ]
Furie, R. [3 ,4 ]
Vital, E. [5 ]
van Vollenhoven, R. [6 ]
Kalunian, K. [7 ]
Mosca, M. [8 ]
Doerner, T. [9 ]
Wallace, D. J. [10 ]
Silk, M. [11 ]
Dickson, C. [11 ]
De la Torre, I. [11 ]
Meszaros, G. [11 ]
Jia, B. [11 ]
Crowe, B. [11 ]
Petri, M. A. [12 ]
机构：
[1] Monash Univ, Ctr Inflammatory Dis, Melbourne, Australia
[2] Univ Occupat & Environm Hlth, Dept Internal Med 1, Kitakyushu, Japan
[3] Northwell Hlth, New Hyde Pk, NY USA
[4] Northwell, Zucker Sch Med, Div Rheumatol, New Hyde Pk, NY USA
[5] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, England
[6] Univ Med Ctr, Clin Immunol & Rheumatol, Amsterdam, Netherlands
[7] Univ Calif La Jolla, Div Rheumatol Allergy & Immunol, La Jolla, CA USA
[8] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy
[9] Charite, Dept Med Rheumatol & Clin Immunol, Berlin, Germany
[10] Univ Calif Los Angeles, Cedars Sinai Med Center, Div Rheumatol Allergy & Immunol, Los Angeles, CA USA
[11] Eli Lilly & Co, NIA, Indianapolis, IN USA
[12] Johns Hopkins Univ, Div Rheumatol, Sch Med, Baltimore, MD USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.1968
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS0190
引用
收藏
页码：327 / 328
页数：2
相关论文
共 50 条
  • [41] OMALIZUMAB EFFICACY AND SAFETY IN NASAL POLYPOSIS: RESULTS FROM TWO PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS
    Gevaert, P.
    Bachert, C.
    Corren, J.
    Mullol, J.
    Han, J.
    Ow, R.
    Islam, L.
    Howard, M.
    Owen, R.
    Wong, K.
    Kaufman, D.
    Omachi, T.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S17 - S17
  • [42] Gaboxadol in angelman syndrome: A double-blind, parallel-group, randomized placebo-controlled phase 3 study
    Keary, Christopher
    Bird, Lynne M.
    de Wit, Marie-Claire
    Hatti, Shivkumar
    Heimer, Gali
    Heussler, Helen
    Kolevzon, Alexander
    Mathews, Adera
    Ochoa-Lubinoff, Cesar
    Tan, Wen-Hann
    Yan, Ying
    Adams, Maxwell
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2023, 47 : 6 - 12
  • [43] A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus
    Werth, V. P.
    Merrill, J. T.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (05) : 964 - 965
  • [44] Efficacy and safety of rofecoxib in patients with chronic low back pain - Results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials
    Katz, N
    Ju, WD
    Krupa, DA
    Sperling, RS
    Rodgers, DB
    Gertz, BJ
    Gimbel, J
    Coleman, S
    Fisher, C
    Nabizadeh, S
    Borenstein, D
    SPINE, 2003, 28 (09) : 851 - 858
  • [45] BARICITINIB IN JUVENILE IDIOPATHIC ARTHRITIS: A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, WITHDRAWAL, EFFICACY AND SAFETY STUDY
    Ramanan, A.
    Quartier, P.
    Okamoto, N.
    Meszaros, G.
    Araujo, J.
    Wang, Z.
    Liao, R.
    Crowe, B.
    Zhang, X.
    Decker, R.
    Keller, S.
    Brunner, H.
    Ruperto, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 207 - 208
  • [46] Baricitinib in Juvenile Idiopathic Arthritis: A Phase 3, Double-Blind, Placebo-Controlled, Withdrawal, Efficacy and Safety Study
    Ramanan, Athimalaipet
    Maire, Pierre Quartier Dit
    Okamoto, Nami
    Meszaros, Gabriella
    Araujo, Joana
    Wang, Zhongkai
    Liao, Ran
    Crowe, Brenda
    Zhang, Xin
    Decker, Rodney
    Keller, Stuart
    Brunner, Hermine
    Ruperto, Nicola
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4385 - 4387
  • [47] Dehydroepiandrosterone in systemic lupus erythematosus - Results of a double-blind, placebo-controlled, randomized clinical trial
    vanVollenhoven, RF
    Engleman, EG
    McGuire, JL
    ARTHRITIS AND RHEUMATISM, 1995, 38 (12): : 1826 - 1831
  • [48] Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
    He, Jing
    Zhang, Ruijun
    Shao, Miao
    Zhao, Xiaozhen
    Miao, Miao
    Chen, Jiali
    Liu, Jiajia
    Zhang, Xiaoying
    Zhang, Xia
    Jin, Yuebo
    Wang, Yu
    Zhang, Shilei
    Zhu, Lei
    Jacob, Alexander
    Jia, Rulin
    You, Xujie
    Li, Xue
    Li, Chun
    Zhou, Yunshan
    Yang, Yue
    Ye, Hua
    Liu, Yanying
    Su, Yin
    Shen, Nan
    Alexander, Jessy
    Guo, Jianping
    Ambrus, Julian
    Lin, Xin
    Yu, Di
    Sun, Xiaolin
    Li, Zhanguo
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (01) : 141 - 149
  • [49] Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study
    Merrill, Joan T.
    Wallace, Daniel J.
    Wax, Stephen
    Kao, Amy
    Fraser, Patricia A.
    Chang, Peter
    Isenberg, David
    ARTHRITIS & RHEUMATOLOGY, 2018, 70 (02) : 266 - 276
  • [50] Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study
    Stohl, William
    Schwarting, Andreas
    Okada, Masato
    Scheinberg, Morton
    Doria, Andrea
    Hammer, Anne E.
    Kleoudis, Christi
    Groark, James
    Bass, Damon
    Fox, Norma Lynn
    Roth, David
    Gordon, David
    ARTHRITIS & RHEUMATOLOGY, 2017, 69 (05) : 1016 - 1027
12345